Search

Your search keyword '"Wang, Hui-Chun"' showing total 14 results
Start Over Author "Wang, Hui-Chun" Publisher wiley
14 results on '"Wang, Hui-Chun"'

6. Retraction notice to “Inosine-Specific Cleavage of RNA for Microarray Analysis of RNA A-to-I Editing Targets” [The Kaohsiung Journal of Medical Sciences 29/4 (April 2013) 179–186]

Author

Huang, Hurng-Wern, primary, Chang, Hsueh-Wei, additional, Wang, Hui-Chun, additional, Lu, Chiu-Jin, additional, Chen, Shaio-Wen, additional, Yi, Szu-Cheng, additional, Wang, Hay-Yan, additional, Cho, Chung-Lung, additional, Wu, Cheng-Hsuan, additional, Yang, Jyuer-Ger, additional, and Tseng, Chao-Neng, additional

Published
2013
Full Text
View/download PDF

11. Burkholderia phymatum is a highly effective nitrogen‐fixing symbiont of Mimosa spp. and fixes nitrogen ex planta

Author

Elliott, Geoffrey N., primary, Chen, Wen‐Ming, additional, Chou, Jui‐Hsing, additional, Wang, Hui‐Chun, additional, Sheu, Shih‐Yi, additional, Perin, Liamara, additional, Reis, Veronica M., additional, Moulin, Lionel, additional, Simon, Marcelo F., additional, Bontemps, Cyril, additional, Sutherland, Joan M., additional, Bessi, Rosana, additional, De Faria, Sergio M., additional, Trinick, Michael J., additional, Prescott, Alan R., additional, Sprent, Janet I., additional, and James, Euan K., additional

Published
2006
Full Text
View/download PDF

14. The Impact of Urate-Lowering Therapy in Post-Myocardial Infarction Patients: Insights From a Population-Based, Propensity Score-Matched Analysis.

Author

Tai CJ, Wu CC, Lee KT, Tseng TG, Wang HC, Chang FR, and Yang YH

Subjects
Aged, Anti-Inflammatory Agents pharmacology, Coronary Artery Bypass methods, Female, Humans, Longitudinal Studies, Male, Percutaneous Coronary Intervention methods, Propensity Score, Retrospective Studies, Taiwan, Treatment Outcome, Myocardial Infarction drug therapy, Myocardial Infarction metabolism, Uric Acid metabolism
Abstract

The role of urate-lowering therapy (ULT) for the primary prevention of cardiovascular (CV) events has been widely discussed, but its evidence for the secondary prevention of myocardial infarction (MI) is limited. Therefore, we conduct a population-based, propensity score-matched cohort study to investigate the CV outcomes among patients with post-MI with and without ULT. A total of 19,042 newly diagnosed in-hospital patients with MI were selected using the Taiwan National Health Insurance Database between January 1, 2005, and December 31, 2016. After 1:1 propensity score matching with covariates, patients with MI with (n = 963) and without (n = 963) ULT were selected for further analysis. The primary outcome was the all-cause mortality and the secondary outcomes were composite CV outcomes, including hospitalization for recurrent MI, stroke, heart failure, and cardiac arrhythmias. ULT users were associated with lower all-cause mortality (adjusted hazard ratio (adjHR), 0.67; 95% confidence interval (CI), 0.51-0.87) compared to the ULT nonusers. In addition, ULT users had a significantly lower risk of recurrent MI, which needed revascularization by percutaneous coronary intervention or coronary artery bypass grafting (adjHR, 0.67; 95% CI, 0.53-0.86) than the ULT nonusers. The primary and secondary outcomes were not different between patients with post-MI who received uricosuric agents and xanthine oxidase inhibitors. The anti-inflammatory effect of ULT plays an essential role in MI management. From a real-world setting, this study shows that ULT is associated with the lower risk of all-cause mortality in patients with post-MI. In addition, the result shows the possible lower incidence of repeat revascularization procedures in the ULT users., (© 2021 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results